Efficacy and safety of chemotherapy regimens with bedaquiline in patients with respiratory tuberculosis: immediate and final results

The objective of the study: to determine the efficacy and safety of chemotherapy regimens with bedaquiline in patients with respiratory tuberculosis in the context of everyday clinical practice with minimal non-inclusion criteria.
Subjects and methods. In a prospective, open-label, non-randomized, single-center trial which included 315 patients, the efficacy and safety of chemotherapy regimens were evaluated, when prescribing a regimen the priority was given to bedaquiline, linezolid, levofloxacin/moxifloxacin, and cycloserine/terizidone. Patients were followed up for at least 24 months, 52.4% suffered from extensive drug resistance of M. tuberculosis (MTB), the majority of patients (50.8%) had a failure of the previous course of treatment, and serious co-morbidities were found in 89.5% of patients.
Results. In 104 patients, the duration of treatment with bedaquiline was limited to standard 24 weeks, in 42 patients, it lasted for 36 weeks, in 56 patients – 48 weeks, and 94 patients received bedaquiline for more than 48 weeks. The increased duration of treatment with bedaquiline for more than 24 weeks provided a significant increase of treatment efficacy (regardless of drug resistance profile) from 66.2% (95% CI 54.4-77.9%) to 84.3% (95% CI 80.0-89.7%). The used regimens were well tolerated: serious adverse events (AE) were observed only in 27.6% of patients, and bedaquiline contribution to their development was not significant (bedaquiline had to be discontinued due to AE in 2.2% of cases). The range of AE practically did not differ from that when using only traditional anti-tuberculosis drugs.

1. Borisov S.E., Ivanushkina T.N., Ivanova D.A., Filippov A.V., Litvinova N.V., Rodina O.V., Garmash Yu.Yu., Safonova S.G., Bogorodskaya E.M. Effectiveness and safety of the Bedaquiline-containing six-month chemotherapy regimens in pulmonary tuberculosis patients. Tuberculosis and socially significant diseases, 2015, no. 3, P. 30-49. (In Russ.)

2. Vasilyeva I. A., Belilovsky E. M., Borisov S. E., Sterlikov S. A. Multi drug resistant tuberculosos in the countries of the outer world and in the Russian Federation. Tuberculosis and Lung Diseases, 2017, Vol. 95, no. 11, P. 5-17. (In Russ.)

3. Gayda А.I., Sveshnikova O.M., Verkhovaya V.N., Makhmaeva S.V., Nikishova E.I., Maryandyshev А.O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, Vol. 96, no. 7, P. 5-9. (In Russ.)

4. Zhukova E.M., Kolpakova T.A., Myshkova E.P., Reykhrud T.A. Experience of using bedaquiline and linezolid in the integral treatment of the pulmonary tuberculosis patient with extensive drug resistance of M. tuberculosis. Tuberculosis and Lung Diseases, 2016, Vol.94, no. 10, P. 62-66. (In Russ.)

5. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Sirturo®. Registracionny nomer: LP-002281. [Instruction for use of the drug Sirturo®. Reg. number LP-002281]. .(Epub.), Avaiable at: http://www.ros-med.info/reestrls/info.php?action=info&id=26223. (Accessed 20.04.2019).(In Russ.)

6. Kondakova M.N., Khabirov V.V., Zhemkov V.F., Shpakovskaya L.R., Daynovets А.V., Elkin А.V. Impact of bedaquiline on the efficiency of comprehensive therapy of respiratory tuberculosis. Tuberculosis and Lung Diseases, 2018, Vol. 6, no. 6, P. 39-43. (In Russ.)

7. Konovаlovа N.M., Odinets V.S., Vаsilenko T.I., Zаdremаylovа T.A. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple andextensive drug resistance. Tuberculosis and Lung Diseases, 2017, Vol. 95, no. 12, P. 49-53. (In Russ.)

8. Morozova T.I., Otpuschennikova O.N., Doktorova N.P., Danilov A.N. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 2016, Vol. 94, no. 2, P. 29-35. (In Russ.)

9. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Licence: CC BY-NC-SA 3.0 IGO. Geneva, World Health Organization, 2018. (Epub.), Avaiable at: http://roftb.ru/netcat_files/doks2018/2018-08-28-WHO_MDRTB_ru.pdf. (Accessed 11.12.2018). (In Russ.)

10. Opredelenie stepeni dostovernosti prichinno-sledstvennoy svyazi «neblagopriyathaya pobochnaya reakcia – lekarstvennoye sredstvo» (klassifikacia y metody): metodicheskie recomendacii [Determination of the degree of reliability of cause-and-effect relationship “adverse drug reaction – drug” (classigication and methods): Guidelines] / Federal service for supervision of health and social development, Moscow, 2008. (Epub.), Available at: http://pandia.ru/text/78/557/9463.php. (Accessed 29.03.2015). (In Russ.)

11. Otraslevye y ekonomicheskie pokazateli protivotubercolioznoy raboty v 2016-2017 gg. Analitichesky obzor osnovnyh pokazateley y statisticheskie materialy [Sectoral and economic indicators of TB control activities in 2016-2017. Analytical review of the main indicators and atistical data] / ed. by S.A. Sterlikov. – Moscow, RIO CNIIOIZ, 2018. – 81 p.

12. Tikhonov A.M., Burаkovа M.V., Vаniev E.V., Romаnov V.V., Vаsilyevа I.A. Efficiency of chemotherapy with bedaquiline in drug resistant pulmonary tuberculosis patients. Tuberculosis and Lung Diseases, 2018, Vol. 96, no. 2, P. 22-26. (In Russ.)

13. Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.А., Ekimenko А.M., Cherenkova M.А., Kudlay D.А. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, Vol. 96, no. 6, P. 45-50.

14. Diacon A.H., Donald P.R., Pym A. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother., 2012, 56(6):3271-3276.

15. Diacon A.H., Pym A., Grobusch M.P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med., 2014, 371(8):723-732.

16. Division of Microbiology and Infection Diseases (DMID) adult toxicity table / Microbiology and Infectious Diseases Clinical Research Policies, Guidance, and Tools // National Institute of Allergy and Infectious Diseases, Bethesda, 2007. (Epub.), Available at: adulttox.pdf. (Accessed 09.07.2013).

17. Falzon D., Gandhi N., Migliori G.B. et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur. Respir. J., 2013, 42(1):156-168.

18. Global Tuberculosis Report 2018. WHO/CDS/TB/2018.20. – Geneva, World Health Organization, 2018. – pp. 95-96.

19. Guglielmetti L., Jaspard M., Le Dû D., Lachâtre M., Marigot-Outtandy D., Bernard C., Veziris N., Robert J., Yazdanpanah Y., Caumes E., Fréchet-Jachym M. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur. Respir. J. – 2017, 49:1601799.

20. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. – Geneva, World Health Organization, 2008.

21. Harari S. Randomised controlled trials and real-life studies: two answers for one question. Eur. Respir. Rev., 2018, 27:180080.

22. Krutikov M., Bruchfeld J., Migliori G. B., Borisov S., Tiberi S. New and repurposed drugs. In: Tuberculosis (ERS Monograph) / ed. by: G.B. Migliori, G. Bothamley, R. Duarte, A. Rendon. – Sheffield, European Respiratory Society, 2018, Chapter 11, 179-204.

23. Kurbatova E.V., Cegielski J.P., Lienhardt C. et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir. Med., 2015, 3(3): 201-209.

24. Ndjeka N., Schnippel K., Master I., Meintjes G., Maartens G., Romero R., Padanilam X., Enwerem M., Chotoo S., Singh N., Hughes J., Variava E., Ferreira H., Te Riele J., Ismail N., Mohr E., Bantubani N., Conradie F. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment. Eur. Respir J., 2018,10:1801528.

25. Safety of Medicines: а guide to detecting and reporting adverse drug reactions. – Geneva: WHO, 2012. − 19 p. (Epub.), Avaiable at: http://whqlibdoc.who.int/hq/2002/WHO_EDM_QSM_2002.2.pdf. (Accessed 29.03.2015).

26. Treatment of tuberculosis: guidelines/ 4th ed. (WHO/HTM/TB/2009.420) – Geneva: WHO, 2009. (Epub.), Available at: http://www.who.int/tb/publications/2009/who_htm_tb_2009_420_beforeprint.pdf. (Accessed 29.03.2015).

27. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. – Geneva: WHO, 2013. − 57 p.

28. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO/CDS/TB/2019.3. – Geneva, World Health Organization, 2019. (Epub.), Available at: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/ (Accessed 29.03.2019).

29. Wu S., Zhang Y., Sun F. et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis // Am. J. Ther. – 2013. (Epub.), Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0061918/ (Accessed 29.03.2019).